Artes Biotechnology and Burnet Institute will join their proprietary technologies to develop a novel vaccine for the Hepatitis C virus. This could create a more affordable solution to reduce the high HCV-related mortality.
Part of the solution could be the development of a prophylactic vaccine, which would protect healthy individuals and prevent re-infection in treated patients. Another important aspect is that it could reduce the economic burden of the disease – preventing disease is usually cheaper than treating it.
This is especially true for HVC, the cure of which (Gilead’s Sovaldi) is priced at around €100,000. Coupled with the high numbers of people infected, paying the therapy has been a challenge to health systems worldwide – including in Europe.